v3.24.3
Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Bayer (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Disaggregation of Revenue [Line Items]        
Revenues $ 3,720.7 $ 3,362.7 $ 10,412.8 $ 9,682.9
Bayer | Rest Of World | Collaboration revenue | Regeneron's share of profits        
Disaggregation of Revenue [Line Items]        
Revenues 367.6 349.9 1,054.5 1,031.0
Bayer | Rest Of World | Collaboration revenue | Reimbursement for manufacturing of ex-U.S. commercial supplies        
Disaggregation of Revenue [Line Items]        
Revenues 23.2 27.2 67.4 79.7
Bayer | Rest Of World | (R&D expense) | Regeneron's obligation for its share of Bayer R&D expenses, net of reimbursement of R&D expenses        
Disaggregation of Revenue [Line Items]        
Revenues $ (11.8) $ (9.7) $ (35.2) $ (35.1)